Sponsored by:

Nuclear Medicine: Page 322

Nuclear medicine must overcome obstacles to flourish in the future
By Wayne Forrest
NEW ORLEANS - The potential for nuclear medicine and molecular imaging to positively affect healthcare on a number of new frontiers in the next 20 years is substantial, but proponents face numerous challenges to make those goals a reality, according to Dr. Richard Wahl of Johns Hopkins Medical Institutes at the opening presention of the 2008 SNM annual meeting.
June 14, 2008
Positron inks distributor deal with Utah firm
By AuntMinnie.com staff writers
PET developer Positron of Houston has signed a sales and marketing agreement with NuView Radiopharmaceuticals.
June 12, 2008
Medrad, PETNet partner for FDG
By AuntMinnie.com staff writers
Contrast injector technology firm Medrad has signed a distribution and comarketing partnership agreement with PETNet Solutions, a subsidiary of Siemens Healthcare.
June 12, 2008
Positron buys Dose Shield, forms Positron Pharmaceuticals
By AuntMinnie.com staff writers
PET developer Positron of Houston has purchased NukeMed subsidiary Dose Shield and formed a new subsidiary, Positron Pharmaceuticals.
June 12, 2008
FDA to give GE's AdreView priority review
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration has designated for priority review GE Healthcare's new drug application for AdreView, a molecular imaging agent for the detection of neuroendocrine tumors in pediatric and adult patients.
June 12, 2008
Molecular Insight starts Trofex trial
By AuntMinnie.com staff writers
Molecular Insight Pharmaceuticals of Cambridge, MA, has begun a phase I clinical trial for its Trofex molecular imaging program for detecting and staging metastatic prostate cancer.
June 11, 2008
UCLA develops new PET probe to monitor immune system
By Wayne Forrest
Researchers at the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center have created a new probe for use with PET that shows promise in monitoring the human immune system and its response to new therapies.
June 11, 2008
2008 06 11 13 21 11 43 Uclapet Probe Crop
Neoprobe starts phase III trial
By AuntMinnie.com staff writers
Gamma camera probe developer Neoprobe has launched a phase III clinical trial for its Lymphoseek radiopharmaceutical agent.
June 8, 2008
IBA, Wilex ink licensing pact
By AuntMinnie.com staff writers
Belgian radiopharmaceutical firm Ion Beam Applications (IBA) has signed a licensing agreement for the worldwide marketing, distribution, and sales of Redectane from Wilex of Munich, Germany.
June 5, 2008
MDS to press AECL on Chalk River reactors
By AuntMinnie.com staff writers
The chief executive of Canadian healthcare company MDS wants the Canadian government and Atomic Energy of Canada (AECL) to reverse the decision to cancel the construction of two nuclear reactors dedicated to medical isotopes.
June 5, 2008
MDS rallies in Q2 results
By AuntMinnie.com staff writers
Despite the past year's reactor shutdown turmoil, Canadian healthcare company MDS and its radioisotope developer MDS Nordion of Kanata, Ontario, posted revenue increases for its second quarter 2008.
June 4, 2008
IsoRay authorizes stock repurchase plan
By AuntMinnie.com staff writers
Medical isotope developer IsoRay has authorized the repurchase of up to 1 million shares of the Richland, WA, company’s common stock.
June 2, 2008
Previous Page
Page 322 of 438
Next Page